Targeting Tumor Mutations for Personalized Cancer Immunotherapy

Опубликовано 11 июля 2019, 16:21

For more information on other ways AWS can help your healthcare and life sciences organization, visit us at: amzn.to/30sSJfE or contact the team at: hcls-startups@amazon.com. We hope that you enjoyed hearing from industry leaders about how they are working to expedite therapy development, incorporate digital therapeutics at scale, and improve patient outcomes.

Gritstone Oncology (NASDAQ: GRTS) is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone leverages 1) a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient’s tumor cells and 2) the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to potentially drive the patient’s immune system to specifically attack and destroy tumors. The company’s lead product candidate, GRANITE-001, is a personalized neoantigen-based immunotherapy beginning Phase 1 clinical testing. Gritstone’s second product candidate, SLATE-001, is a shared neoantigen (“off-the-shelf”) immunotherapy which is advancing towards the clinic. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone’s BiSAb program is currently in lead optimization.